Sheraton Seattle Hotel Floorplan
Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2017
Here are the related meetings in 2020:
Cancer Epigenetics: New Mechanisms and Therapeutic Opportunities (J4)
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Epigenetics and Human Disease: Progress from Mechanisms to Therapeutics (A9)
Organizer(s) Johnathan R. Whetstine, Jessica K. Tyler and Rab K. Prinjha
January 29—February 2, 2017
Sheraton Seattle Hotel • Seattle, Washington USA
Discounted Abstract Deadline: Sep 29, 2016
Abstract Deadline: Oct 27, 2016
Scholarship Deadline: Sep 29, 2016
Discounted Registration Deadline: Nov 30, 2016
Sponsored by Incyte Corporation, Merck & Co., Inc., Taylor & Francis and Vertex Pharmaceuticals Incorporated
Summary of Meeting:
Epigenetics impacts human health and disease. Data from a range of diseases (cancer, neurological and immunological disorders) have documented mutations, altered expression and copy number alterations in numerous epigenetic factors (histones, DNA and chromatin modifying enzymes, reader proteins, chromatin modulators and noncoding RNAs). Genome-wide data has also illustrated the relationship between altered epigenetic states (e.g., modified DNA and histones) and disease onset and progression. Therefore, there is a need to discover the molecular mechanisms and interplay between epigenetic regulators. These mechanistic insights will shed light on the impact epigenetic regulators have on cellular homeostasis, while resolving their pathogenic contribution to disease states. This meeting is aimed at interrogating the most current knowledge surrounding the epigenetic events modulating nuclear function (gene expression regulation, enhancer modulation, domains and structural organization as well as cell division and differentiation), while relating this to developmental and disease models. In addition, this meeting will highlight the impact that preclinical and clinical epigenetic therapeutics have on a panel of diseases including cancer and neurological disorders. By presenting these various aspects associated with epigenetics and diverse disease, this unique forum should promote dynamic discussions, interactions and collaborations that will impact our understanding of disease and possible treatment strategies. Opportunities for trainee career development, networking and oral presentations are provided by a “Focus on Junior Scientists” session, a panel discussion and mixer with scientific editors and another with industry scientists.
View Scholarships/Awards
Epigenetics impacts human health and disease. Data from a range of diseases (cancer, neurological and immunological disorders) have documented mutations, altered expression and copy number alterations in numerous epigenetic factors (histones, DNA and chromatin modifying enzymes, reader proteins, chromatin modulators and noncoding RNAs). Genome-wide data has also illustrated the relationship between altered epigenetic states (e.g., modified DNA and histones) and disease onset and progression. Therefore, there is a need to discover the molecular mechanisms and interplay between epigenetic regulators. These mechanistic insights will shed light on the impact epigenetic regulators have on cellular homeostasis, while resolving their pathogenic contribution to disease states. This meeting is aimed at interrogating the most current knowledge surrounding the epigenetic events modulating nuclear function (gene expression regulation, enhancer modulation, domains and structural organization as well as cell division and differentiation), while relating this to developmental and disease models. In addition, this meeting will highlight the impact that preclinical and clinical epigenetic therapeutics have on a panel of diseases including cancer and neurological disorders. By presenting these various aspects associated with epigenetics and diverse disease, this unique forum should promote dynamic discussions, interactions and collaborations that will impact our understanding of disease and possible treatment strategies. Opportunities for trainee career development, networking and oral presentations are provided by a “Focus on Junior Scientists” session, a panel discussion and mixer with scientific editors and another with industry scientists.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
The meeting will begin on Sunday, January 29 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, February 2 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, February 3 in order to fully experience the meeting.
SUNDAY, JANUARY 29
MONDAY, JANUARY 30
TUESDAY, JANUARY 31
WEDNESDAY, FEBRUARY 1
THURSDAY, FEBRUARY 2
FRIDAY, FEBRUARY 3
Conference Program Print | View meeting in 12 hr (am/pm) time
The meeting will begin on Sunday, January 29 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, February 2 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, February 3 in order to fully experience the meeting.
SUNDAY, JANUARY 29
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.
08:30—09:30
Welcome and Keynote Address
*
Johnathan R. Whetstine,
Fox Chase Cancer Center, USA
*
Jessica K. Tyler,
Weill Cornell Medicine, USA
*
Rab K. Prinjha,
GlaxoSmithKline, UK
Rudolf Jaenisch,
Whitehead Institute for Biomedical Research, USA
Epigenetics, Stem Cells and Disease Research
Epigenetics, Stem Cells and Disease Research
09:30—11:45
Epigenetics and Genome Organization
*
Bradley E. Bernstein,
Massachusetts General Hospital, USA
Thomas Misteli,
NCI, National Institutes of Health, USA
Deep Imaging of the Genome
Deep Imaging of the Genome
Coffee Break
Bas van Steensel,
Netherlands Cancer Institute, Netherlands
Architecture, Dynamics and Function of Genome - Nuclear Lamina Interactions
Architecture, Dynamics and Function of Genome - Nuclear Lamina Interactions
Kadir Akdemir,
University of Texas MD Anderson Cancer Center, USA
Short Talk: Spatial Organization of the Genome & Structural Alterations in Human Cancers
Short Talk: Spatial Organization of the Genome & Structural Alterations in Human Cancers
Robert Hansel-Hertsch,
University of Cambridge, UK
Short Talk: G-Quadruplex Structures Mark Human Regulatory Chromatin
Short Talk: G-Quadruplex Structures Mark Human Regulatory Chromatin
Janneke Peeters,
University Medical Center Utrecht, Netherlands
Short Talk: Enhancers in Autoimmune Disease Cells Contribute to Disease Pathogenesis and Can be Targeted to Reduce Autoimmunity
Short Talk: Enhancers in Autoimmune Disease Cells Contribute to Disease Pathogenesis and Can be Targeted to Reduce Autoimmunity
17:00—19:00
From Epigenomics to Disease
*
Henk G. Stunnenberg,
Radboud University, Netherlands
Bradley E. Bernstein,
Massachusetts General Hospital, USA
Epigenetic Mechanisms of Tumor Initiation and Evolution
Epigenetic Mechanisms of Tumor Initiation and Evolution
Joseph F. Costello,
University of California, San Francisco, USA
Losing Driver Mutations, Gaining Insight into Epigenome Evolution
Losing Driver Mutations, Gaining Insight into Epigenome Evolution
John A. Stamatoyannopoulos,
Altius Institute for Biomedical Sciences, USA
A Roadmap to the Living Genome
A Roadmap to the Living Genome
Daniel S. Day,
Whitehead Institute, USA
Short Talk: Tumor Progression through Sequential Disruption of Insulated Neighborhoods
Short Talk: Tumor Progression through Sequential Disruption of Insulated Neighborhoods
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:30—11:45
Epigenetic Modification Dynamics: Gateway to Understanding Disease
*
Jessica K. Tyler,
Weill Cornell Medicine, USA
Henk G. Stunnenberg,
Radboud University, Netherlands
Epigenomics Uncovers Dysregulated Regulatory Pathways
Epigenomics Uncovers Dysregulated Regulatory Pathways
Shelley L. Berger,
University of Pennsylvania, USA
Histone Acetylation Pathways in Learning and Memory
Histone Acetylation Pathways in Learning and Memory
Coffee Break
Anne Schaefer,
Mount Sinai School of Medicine, USA
Polycomb Repressive Complex 2 (PRC2) Silences Genes Responsible for Neurodegeneration
Polycomb Repressive Complex 2 (PRC2) Silences Genes Responsible for Neurodegeneration
Robert E. Kingston,
Massachusetts General Hospital, USA
Nucleosome Compaction as a Regulatory Mechanism during Development
Nucleosome Compaction as a Regulatory Mechanism during Development
Panagiotis Ntziachristos,
Northwestern University, USA
Short Talk: Targeting Deubiquitination in Acute Leukemia
Short Talk: Targeting Deubiquitination in Acute Leukemia
Woojin An,
University of Southern California, USA
Short Talk: MacroH2A Suppresses Prostate Cancer Bone Metastasis through Cooperation with HP1 and H1.2
Short Talk: MacroH2A Suppresses Prostate Cancer Bone Metastasis through Cooperation with HP1 and H1.2
17:00—19:00
Chromatin Modifiers, Development and Disease
*
Anne Schaefer,
Mount Sinai School of Medicine, USA
Johnathan R. Whetstine,
Fox Chase Cancer Center, USA
Epigenetic Mechanisms Impact Cell Cycle and Somatic DNA Copy Number
Epigenetic Mechanisms Impact Cell Cycle and Somatic DNA Copy Number
Peter W. Lewis,
University of Wisconsin-Madison, USA
Short Talk: H3 K36M Oncohistone Promotes Sarcomagenesis through Altered Methylation Landscape
Short Talk: H3 K36M Oncohistone Promotes Sarcomagenesis through Altered Methylation Landscape
David M. Truong,
New York University Langone Medical Center, USA
Short Talk: Resetting the Yeast Epigenome with Human Nucleosomes
Short Talk: Resetting the Yeast Epigenome with Human Nucleosomes
Kimberly J. Cocce,
Duke University, USA
Short Talk: Genome Wide Profiling Identifies a FoxA1/GRHL2 Interaction that Functions as a Mediator of Endocrine Therapy Resistance in a Model of Luminal Breast Cancer
Short Talk: Genome Wide Profiling Identifies a FoxA1/GRHL2 Interaction that Functions as a Mediator of Endocrine Therapy Resistance in a Model of Luminal Breast Cancer
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:30—11:45
Epigenetics and Cell States
*
François Fuks,
Université Libre de Bruxelles, Belgium
Emily Bernstein,
Mount Sinai School of Medicine, USA
Epigenetic Sensitivities in Cancer
Epigenetic Sensitivities in Cancer
Luciano Di Croce,
CRG - Center for Genomic Regulation, Spain
Unveiling Polycomb Functions in Stem Cells and Cancer
Unveiling Polycomb Functions in Stem Cells and Cancer
Coffee Break
Maria-Elena Torres-Padilla,
Helmholtz Centre Munich, Germany
Epigenetic Mechanisms in Early Mammalian Development
Epigenetic Mechanisms in Early Mammalian Development
Gerald R. Crabtree,
Stanford University, USA
Chromatin Remodeling: Insights from the Genetics of Human Disease and New Methods
Chromatin Remodeling: Insights from the Genetics of Human Disease and New Methods
Elizabeth Heller,
University of Pennsylvania, USA
Short Talk: Targeted Neuroepigenetic Editing of Cdk5 Regulates Behavior
Short Talk: Targeted Neuroepigenetic Editing of Cdk5 Regulates Behavior
Ana Patricia Gomes,
Weill Cornell Medicine, USA
Short Talk: The CAF1 Complex Promotes Tumor Progression through Re-Distribution of Histone H3.3 in the Chromatin
Short Talk: The CAF1 Complex Promotes Tumor Progression through Re-Distribution of Histone H3.3 in the Chromatin
14:30—16:30
Workshop: Breakthroughs in Technology and Disease
*
Cheryl Arrowsmith,
University of Toronto, Canada
Hatice Efsun Arda,
National Institutes of Health, USA
Lineage Specific Regulomes of the Human Pancreas
Lineage Specific Regulomes of the Human Pancreas
Victoria T. Le,
New York Genome Center, USA
Finding Translocations in Cancer Genomes using Chromatin Interaction Data
Finding Translocations in Cancer Genomes using Chromatin Interaction Data
Tonya Marie Gilbert,
Massachusetts General Hospital, USA
In vivo HDAC Imaging in Schizophrenia using Combined MR-PET
In vivo HDAC Imaging in Schizophrenia using Combined MR-PET
Ari Allyn-Feuer,
University of Michigan Medical School, USA
The Pharmacogenomics Informatics Pipeline: An Integrative Multi-Omics Platform for Variant Discovery
The Pharmacogenomics Informatics Pipeline: An Integrative Multi-Omics Platform for Variant Discovery
Nabieh Ayoub,
Technion -Israel Institute of Technology, Israel
Characterizing the Biological Functions of KDM4A-D Interactions with RNA Molecules
Characterizing the Biological Functions of KDM4A-D Interactions with RNA Molecules
Shinya Oki,
Kyoto University, Japan
The Transcription Factor Landscape Decodes the Enhancers and Risk Variants in Non-Coding Regions
The Transcription Factor Landscape Decodes the Enhancers and Risk Variants in Non-Coding Regions
Yael David,
Memorial Sloan Kettering Cancer Center, USA
Towards Synthetic Chromatin: Modifying Histones In Live Cells Using Protein Trans-Splicing
Towards Synthetic Chromatin: Modifying Histones In Live Cells Using Protein Trans-Splicing
17:00—19:15
Epigenetic States and RNA
*
Emily Bernstein,
Mount Sinai School of Medicine, USA
Tony Kouzarides,
University of Cambridge, UK
Modifications of RNA: Their Function and Role in Cancer
Modifications of RNA: Their Function and Role in Cancer
Ramin Shiekhattar,
University of Miami, USA
Targeting Integrator in Cancer
Targeting Integrator in Cancer
Ali Shilatifard,
Northwestern University, USA
Principles of Epigenetics and Chromatin in Development and Human Disease
Principles of Epigenetics and Chromatin in Development and Human Disease
François Fuks,
Université Libre de Bruxelles, Belgium
Short Talk: Transcriptome-Wide Distribution and Function of RNA Hydroxymethylcytosine
Short Talk: Transcriptome-Wide Distribution and Function of RNA Hydroxymethylcytosine
Guillermo Barreto,
Max Planck Institute for Heart and Lung Research, Germany
Short Talk: Nuclear miRNA/exosome-Mediated Transcriptional Silencing within the Context of TGFB1 Signaling and Idiopathic Pulmonary Fibrosis
Short Talk: Nuclear miRNA/exosome-Mediated Transcriptional Silencing within the Context of TGFB1 Signaling and Idiopathic Pulmonary Fibrosis
08:30—11:45
Targeting Epigenetics
*
Johnathan R. Whetstine,
Fox Chase Cancer Center, USA
Rab K. Prinjha,
GlaxoSmithKline, UK
Clinical Progression of BET Inhibitors
Clinical Progression of BET Inhibitors
Cheryl Arrowsmith,
University of Toronto, Canada
Probing the Epigenome for New Therapeutic Opportunities
Probing the Epigenome for New Therapeutic Opportunities
Coffee Break
Alexander Tarakhovsky,
Rockefeller University, USA
Uncovering Histone Mimics and Disease
Uncovering Histone Mimics and Disease
Jesse J. Smith,
Omega Therapeutics, USA
The EZH2 Inhibitor Tazemetostat as a Potential Therapeutic for Non-Hodgkin Lymphoma and Genetically Defined Solid Tumors
The EZH2 Inhibitor Tazemetostat as a Potential Therapeutic for Non-Hodgkin Lymphoma and Genetically Defined Solid Tumors
Norman Wong,
Resverlogix Corp, Canada
Short Talk: Selective BET Inhibitors are Useful for Normalizing Inflammation Leading to Reduced Cardiovascular Disease (CVD) in Humans and in an Animal Model of Rheumatoid Arthritis
Short Talk: Selective BET Inhibitors are Useful for Normalizing Inflammation Leading to Reduced Cardiovascular Disease (CVD) in Humans and in an Animal Model of Rheumatoid Arthritis
Shaokun Shu,
Dana-Farber Cancer Institute, USA
Short Talk: Response and Resistance to BET Bromodomain Inhibitors in Triple Negative Breast Cancer
Short Talk: Response and Resistance to BET Bromodomain Inhibitors in Triple Negative Breast Cancer
17:00—18:45
Epigenetics and Therapy
*
Rab K. Prinjha,
GlaxoSmithKline, UK
Tamara Maes,
Oryzon Genomics, Spain
Development of Lysine-Specific Demethylase Inhibitors for Oncological and Neurodegenerative Disease
Development of Lysine-Specific Demethylase Inhibitors for Oncological and Neurodegenerative Disease
Erica Korb,
Rockefeller University, USA
Short Talk: Treatment of Fragile X Syndrome with the BET Inhibitor Jq1
Short Talk: Treatment of Fragile X Syndrome with the BET Inhibitor Jq1
Dineo Khabele,
Vanderbilt University, USA
Novel Epigenetic Drug Regimens to Enhance PARP Inhibitor Efficacy in Ovarian Cancer
Novel Epigenetic Drug Regimens to Enhance PARP Inhibitor Efficacy in Ovarian Cancer
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.
*Session Chair †Invited, not yet responded.
We gratefully acknowledge support for this conference from:
Keystone Symposia thanks our Sponsors(s) for generously supporting this meeting:
|
|
|
|
We gratefully acknowledge additional support for this conference from:
|
|
|
|
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Corporate Relations, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org, Phone:+1 970-262-1179 |
